India’s Ranbaxy To Continue Acquisitions Despite Daiichi Purchase
This article was originally published in PharmAsia News
Executive Summary
Despite a pending buyout by Japan's Daiichi Sankyo, India's Ranbaxy Laboratories plans to follow through on acquisition plans made before the Daiichi offer. Ranbaxy CEO Malvinder Mohan Singh said that even as a Daiichi subsidiary, Ranbaxy would continue to acquire other companies and attempt to grow as a drug maker with separate ownership and management. Singh also denied assertions the merger would harm Ranbaxy's business in India. He said changes in shareholders and foreign ownership would not make Ranbaxy a non-Indian company. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.